SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-038468
Filing Date
2024-02-16
Accepted
2024-02-16 16:05:58
Documents
17
Period of Report
2024-02-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d772979d8k.htm   iXBRL 8-K 32056
2 EX-10.1 d772979dex101.htm EX-10.1 231490
3 EX-99.1 d772979dex991.htm EX-99.1 11254
7 GRAPHIC g772979g0216210027367.jpg GRAPHIC 3765
  Complete submission text file 0001193125-24-038468.txt   458245

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fusn-20240216.xsd EX-101.SCH 2854
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fusn-20240216_lab.xml EX-101.LAB 18690
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fusn-20240216_pre.xml EX-101.PRE 11695
18 EXTRACTED XBRL INSTANCE DOCUMENT d772979d8k_htm.xml XML 3803
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39344 | Film No.: 24648338
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)